Arista Wealth Management LLC Sells 4,000 Shares of AstraZeneca PLC $AZN

Arista Wealth Management LLC decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 42.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,342 shares of the company’s stock after selling 4,000 shares during the period. Arista Wealth Management LLC’s holdings in AstraZeneca were worth $410,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in AZN. Prospera Financial Services Inc lifted its stake in AstraZeneca by 2.0% during the third quarter. Prospera Financial Services Inc now owns 115,223 shares of the company’s stock worth $8,840,000 after purchasing an additional 2,265 shares during the last quarter. Oppenheimer & Co. Inc. raised its holdings in shares of AstraZeneca by 7.4% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 29,738 shares of the company’s stock worth $2,281,000 after buying an additional 2,057 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in shares of AstraZeneca by 7.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 116,460 shares of the company’s stock worth $8,935,000 after buying an additional 8,043 shares during the last quarter. Signature Estate & Investment Advisors LLC boosted its stake in AstraZeneca by 14.2% in the third quarter. Signature Estate & Investment Advisors LLC now owns 10,343 shares of the company’s stock valued at $794,000 after buying an additional 1,290 shares in the last quarter. Finally, Azzad Asset Management Inc. ADV grew its position in AstraZeneca by 0.6% in the third quarter. Azzad Asset Management Inc. ADV now owns 64,714 shares of the company’s stock valued at $4,965,000 after acquiring an additional 368 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Down 2.4%

Shares of AstraZeneca stock opened at $188.40 on Tuesday. The stock’s 50-day moving average is $103.79 and its 200 day moving average is $89.45. AstraZeneca PLC has a one year low of $122.48 and a one year high of $193.97. The firm has a market cap of $292.19 billion, a price-to-earnings ratio of 62.59, a PEG ratio of 1.59 and a beta of 0.34. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. TD Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, December 9th. Citigroup assumed coverage on shares of AstraZeneca in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. Jefferies Financial Group initiated coverage on AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating for the company. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, January 21st. Finally, Guggenheim reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Wednesday, December 3rd. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.